Business Wire

DeepGreenX Group and Hues Capital Launch $10 Billion USD Fund to Accelerate AI, Green Energy, and Computing Power

9.12.2024 14:00:00 EET | Business Wire | Press release

Share

DeepGreenX Group Inc. (“DeepGreenX,” “DXG,” or the “Company”), an AI-enabled green energy and technology company, and Hues Capital (“Hues”), a leading capital provider enabling financial technology ecosystems, AI, and green energy enterprises, jointly announced the formation of a new $10 billion USD fund (the “Fund”) to drive global advancements in AI, green energy, and computing power and accelerate sustainability initiatives worldwide.

DeepGreenX and Hues will each hold a 50% stake and act as co-general partners in the $10 billion USD DXG-Hues parent fund, which will be based in the EU and comprise two $5 billion USD sub-funds: the DXG-Hues AI Computing Infrastructure Fund and the DXG-Hues AI Energy Fund. The former will focus on global investments in AI computing power and green energy infrastructure projects, while the latter will target emerging enterprises in the fields of AI ecosystems, fintech, and green energy.

This initiative will bring together seasoned professionals with deep expertise in technology and finance. The Fund’s leadership team will include Miao Wei, former Vice President of Alibaba Cloud, and Dr. Chen Jidong, former Vice President of Ant Group's Digital Technology Division and Chief Product Officer of Security Technology. In connection with the formation of the Fund, Hues founder, Chairman, and Chief Executive Officer Dr. Jim Lai will join the Board of Directors of DeepGreenX.

Dr. Lai was previously Vice President of Tencent, where he led the Financial Internet Technology (FiT) division and contributed to the creation of WeChat Pay, WeChat Red Envelope, and the management of Tencent’s trillion-yuan Wealth Management Platform. He also played a critical role in Tencent's investment strategy, investing into dozens of WeChat Pay ecosystem companies founded by visionary entrepreneurs. He collaborated on incubating and scaling numerous industry-leading unicorns, many of which have gone public, including those focused on AI-driven big data and financial technology, as well as world-leading financial institutions. In his role as a director for several post-investment companies on behalf of Tencent, Dr. Lai has been instrumental in fostering collaboration and synergy within Tencent’s WeChat Pay ecosystem. These companies have also consistently achieved unicorn status, gone public, and generated significant returns for their investors.

“We are thrilled to launch this new Fund with Hues, which is a product of our shared vision that new, innovative capital sources are required for these new, innovative ecosystems. With this collaboration, we are taking a bold and strategic step forward in harnessing AI-driven computing power, advancing sustainable energy solutions, and catalyzing innovative financial systems,” said Barclay Knapp, CEO of DeepGreenX. “We believe this Fund will provide substantial financial resources to high-impact enterprises and projects, accelerating the transition to a global green economy while promoting long-term sustainability.”

DeepGreenX is a rapidly developing international platform company connecting green energy, nature-based and real-world assets (RWA), sustainable computing power, and AI developer communities to new-era digital trading and banking systems. The Company deploys an AI platform-as-a-service (AI PaaS) model to extract and convert sustainability, RWA, and other data into verified digital financial instruments such as renewable energy certificates (REC), tokens, and its own-branded DXG Certificates, which the Company then transacts and monetizes on digital trading and banking systems on behalf of its enterprise clients. Alongside its platform, DeepGreenX is facilitating the synergistic development of human intelligence plus AI applications via a 190,000-person strong AI developer community.

“Hues’ depth of expertise will be instrumental in supporting DeepGreenX’s efforts to establish and operate a global CBDC clearing network,” said Dr. Lai. “This collaboration will also strengthen strategic integration across both companies’ ecosystems, spanning portfolios in AI, green energy, and computing power.”

Hues boasts a foundation of global institutional LPs, with a mission to enable large-scale financial technology ecosystems, AI technology, and green energy enterprises to scale internationally. It seeks to build a globally integrated ecosystem that bridges AI, financial technology, and sustainable energy solutions. It is led by Dr. Lai, former founding Chairman of Fusion Bank, with stakeholders such as Tencent, the Hong Kong Stock Exchange, and ICBC (Asia).

About DeepGreenX

Founded in 2020 and headquartered in Seoul, DeepGreenX Group Inc. is a digital transformation company providing AI and financialization solutions for sustainability initiatives and real-world assets worldwide. With developing operations in 20 cities across four continents, DeepGreenX employs proprietary AI technology and a PaaS model to capture and verify attractive data assets, digitally convert those assets into digital financial products, and then transact with them on global digital trading and banking platforms on behalf of its enterprise customers. For more information on DeepGreenX, visit: www.DeepGreenX.com.

About Hues Capital

Founded in 2023, Hues Capital is a PE fund management company with an internet background, aimed at helping entrepreneurs develop their own companies and businesses in the internet ecosystems of China, Japan, and Southeast Asia. The founder and team of Hues Capital have created the largest mobile payment ecosystem covering the world, incubating and empowering numerous successful unicorn enterprises in the FinTech industry. The current investment areas of Hues Capital mainly include three directions: FinTech, AI, Supercomputing Data Center and New energy EV.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241208029753/en/

Contacts

DeepGreenX:
Prosek Partners
Kiki Tarkhan / Forrest Gitlin
DeepGreenX@prosek.com

Hues Capital:
Rongping Hu
enquiry@hues.capital
+86 755 2267 0610

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye